223. Multidomain behavioural profiling in the Flinders Sensitive Line rat and response to escitalopram or a novel butyrylcholinesterase inhibitor: focus on anhedonia
Abstract Background Anhedonia is a core symptom of major depressive disorder (MDD) but is challenging to model and to treat. First-line serotonergic antidepressants, e.g., escitalopram (ESC), often show limited efficacy in certain reward-related domains. Anhedonia is multi-dimensional, encompassing motivational drive,...